Last update 21 Nov 2024
AL-8326
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism Aurora B inhibitors(Serine/threonine-protein kinase Aurora-B inhibitors), FGFRs antagonists(Fibroblast growth factor receptors antagonists), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationSpecial Review Project (CN), Breakthrough Therapy (CN) |
Login to view timeline
Related
15
Clinical Trials associated with AL-8326AL8326片治疗至少接受二线治疗方案后疾病进展或复发的小细胞肺癌患者的III期临床研
究
[Translation] Phase III clinical study of AL8326 tablets in the treatment of patients with small cell lung cancer who have had disease progression or recurrence after at least two lines of treatment
Phase III Clinical Study of AL8326 Tablets in Patients With Advanced or Recurrent Small Cell Lung Cancer After at Least Prior Second-line Treatment
A Phase 2 Evaluation of the Safety and Efficacy of AL8326 in ≥2nd Line Small Cell Lung Cancer (SCLC) Treatment
100 Clinical Results associated with AL-8326
Login to view more data
100 Translational Medicine associated with AL-8326
Login to view more data
100 Patents (Medical) associated with AL-8326
Login to view more data
100 Deals associated with AL-8326
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Small Cell Lung Cancer | Phase 3 | CN | 26 Oct 2023 | |
| Bile Duct Neoplasms | Phase 1 | CN | 01 Jun 2022 | |
| Bladder Cancer | Phase 1 | CN | 01 Jun 2022 | |
| Non-Small Cell Lung Cancer | Phase 1 | CN | 03 Dec 2021 | |
| Advanced cancer | Phase 1 | CN | 12 Dec 2018 | |
| Pancreatic Cancer | Phase 1 | CN | 12 Dec 2018 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | CN | 17 Aug 2017 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT04890795 (ASCO2023) Manual  | Phase 1/2 | Small Cell Lung Cancer Third line | 30 | (izaayrbrvq) = wpodvqklwp wjuagwxqiv (mxlrdmhagw ) View more | Positive | 26 May 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free